Offer - Urjas Oil for just ₹ 1 X
Mirabig S 25 Tablet ER (10) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Mirabig S 25 Tablet ER (10) safe for pregnant women?
Mirabig S Tablet may cause moderate side effects during pregnancy. If you feel its harmful effects, then stop taking this drug immediately, and do not take Mirabig S Tablet again without your doctor's advice.
Is the use of Mirabig S 25 Tablet ER (10) safe during breastfeeding?
Mirabig S Tablet can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Mirabig S 25 Tablet ER (10) on the Kidneys?
Mirabig S Tablet has very mild side effects on the kidneys.
What is the effect of Mirabig S 25 Tablet ER (10) on the Liver?
Very few cases of side effects of Mirabig S Tablet on the liver have been reported.
What is the effect of Mirabig S 25 Tablet ER (10) on the Heart?
Mirabig S Tablet has very mild side effects on the heart.
If you are suffering from any of the following diseases, you should not take Mirabig S 25 Tablet ER (10) unless your doctor advises you to do so -
Is this Mirabig S 25 Tablet ER (10) habit forming or addictive?
No, there is no any evidence that Mirabig S 25 Tablet ER (10) is addictive.
Interaction between Food and Mirabig S 25 Tablet ER (10)
Taking Mirabig S 25 Tablet ER (10) with food does not harm your health.
Interaction between Alcohol and Mirabig S 25 Tablet ER (10)
Taking Mirabig S 25 Tablet ER (10) with alcohol can have severely harmful effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 864
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Myrbetriq (mirabegron)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Betmiga® (mirabegron)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; VESIcare® (solifenacin succinate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1151